Natixis Coherus Bio Sciences, Inc. Transaction History
Natixis
- $19.1 Billion
- Q1 2024
Shares
1 transactions
Others Institutions Holding CHRS
# of Institutions
148Shares Held
82.9MCall Options Held
184KPut Options Held
255K-
Black Rock Inc. New York, NY11.2MShares$15.6 Million0.0% of portfolio
-
Rubric Capital Management LP New York, NY10.4MShares$14.5 Million0.85% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$14 Million0.0% of portfolio
-
Temasek Holdings (Private) LTD Singapore, U07.38MShares$10.3 Million0.1% of portfolio
-
Kohlberg Kravis Roberts & Co. L.P. New York, NY3.04MShares$4.22 Million0.31% of portfolio
About Coherus BioSciences, Inc.
- Ticker CHRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,724,600
- Market Cap $108M
- Description
- Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...